The Impact of Glucocorticoid Replacement Regimens on Metabolic Outcome and Comorbidity in Hypopituitary Patients
The DOI matches its Crossref record; 44 of the 48 references it cites were found in a registry or an index.
Abstract
Background: Hypopituitary patients with untreated GH deficiency and patients on inappropriately high doses of glucocorticoid (GC) share certain clinical features. Objective: The aim of the study was to examine the influence of GC substitution on clinical characteristics in hypopituitary patients before and after GH replacement therapy. Method: A total of 2424 hypopituitary patients within the KIMS (Pfizer International Metabolic Database) were grouped according to ACTH status. Comparisons were performed between subjects on hydrocortisone (HC) (n = 1186), cortisone acetate (CA) (n = 487), and prednisolone/dexamethasone (n = 52), and ACTH-sufficient patients (AS) (n = 717) before and after 1 yr of GH treatment in terms of body mass index, waist and hip circumference, blood pressure, glucose, glycosylated hemoglobin (HbA1c), serum lipids, IGF-I, and comorbidity. Hydrocortisone equivalent (HCeq) doses were calculated, and measurements were adjusted for sex and age. Results: At baseline, the HC group had increased total cholesterol, triglycerides, waist circumference, and HbA1c, and the prednisolone/dexamethasone group had increased waist/hip ratio as compared with AS. After HCeq dose adjustment, the HC group retained higher HbA1c than the CA group. GC-treated patients showed a dose-related increase in serum IGF-I, body mass index, triglycerides, low-density lipoprotein cholesterol and total cholesterol levels. Subjects with HCeq doses less than 20 mg/d (n = 328) at baseline did not differ from AS in metabolic endpoints. The 1-yr metabolic response to GH was similar in all GC groups and dose categories. All new cases of diabetes (n = 12), stroke (n = 8), and myocardial infarction (n = 3) during GH treatment occurred in GC-treated subjects. Conclusion: HCeq doses of at least 20 mg/d in adults with hypopituitarism are associated with an unfavorable metabolic profile. CA replacement may have metabolic advantages compared with other GCs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Retrospective studies of patients taking higher doses of glucocorticoids in some cases, including prednisolone or dexamethasone, appear to show a tendency to adverse metabolic consequences including weight gain, dyslipidemia, and diabetes mellitus (102).”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [102]
In the citing paper
“When patients cut their GC dose in half (from 20-30 mg to 10-15 mg HC daily), mean body weight decreased by 7.1 kg after 6-12 months (209).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [209]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 1×
“Serum total cholesterol (TC) (15), triglycerides (16), and high-density lipoprotein cholesterol (HDL-C) (17) were measured as previously described, and low-density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald formula (18).”
MethodSerum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide.
Fossati, P., & Prencipe, L. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.10.2077 · Cited by 2,905 · cited 1×
“Serum total cholesterol (TC) (15), triglycerides (16), and high-density lipoprotein cholesterol (HDL-C) (17) were measured as previously described, and low-density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald formula (18).”
MethodCholesterol determination in high-density lipoproteins separated by three different methods.
Lopes-Virella, M. F., Stone, P., Ellis, S., & Colwell, J. A. (1977) · Clinical Chemistry · doi:10.1093/clinchem/23.5.882 · Cited by 1,841 · cited 5×
“This study was carried out in Eu- First Published Online August 8, 2006 Abbreviations: AE, Adverse event; AS, ACTH-sufficient (patients); BMI, body mass index; BP, blood pressure; CA, cortisone acetate; CI, confidence interval; DHEA, dehydroepiandrostenedione; DHEAS, DHEA sulfate; DM, diabetes mellitus; DX, dexamethas…”
MethodInfluentialGlucocorticoid-Induced Osteoporosis: Pathogenesis and Management
Lukert, B. P., & Raisz, L. G. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-352 · Cited by 1,066
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006 · cited 1×
“This could explain some of the metabolic features and increased cardiovascular mortality associated with severe GHD (9).”
BackgroundThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“ease, with no safe lower dose threshold (38, 39).”
BackgroundDaily cortisol production rate in man determined by stable isotope dilution/mass spectrometry
ESTEBAN, N. V., LOUGHLIN, T., YERGEY, A. L., ZAWADZKI, J. K., BOOTH, J. D., WINTERER, J. C., & LORIAUX, D. L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-39 · Cited by 481 · cited 8×
“Recently, a reduction in GC dose has been advocated because physiological cortisol production has been shown to be lower than previously thought (10).”
BackgroundInfluentialCanalis, E. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.10.3441 · Cited by 463
Brabant, G., von zur Mühlen, A., Wüster, C., Ranke, M. B., Kratzsch, J., Kiess, W., Ketelslegers, J.-M., Wilhelmsen, L., Hulthén, L., Saller, B., et al. (2003) · Hormone Research in Paediatrics · doi:10.1159/000071871 · Cited by 360 · cited 1×
“In subsequent years, a chemiluminescence immunoassay was used (Nichols Advantages system) (20).”
MethodSelf-citation
Cited by
Items 201–300 of 346
Kiko, N., & Kalhan, A. (2020) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000508321 · Cited by 9
Biscotto, I. P., Costa‐Hong, V., Batista, R. L., Mendonca, B. B., Arnhold, I. J. P., Bortolotto, L. A., & Carvalho, L. R. S. (2020) · Pituitary · doi:10.1007/s11102-020-01099-z · Cited by 9
Paisley, A. N., Rowles, S., Brandon, D. D., & Trainer, P. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2392 · Cited by 9
Bancos, I., Kim, H., Cheng, H. K.-H., Rodríguez-Lee, M., Coope, H., Cicero, S., Goldsmith, H., Lin, V. H., & Jeha, G. S. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2450423 · Cited by 9
Management of Glucocorticoid Replacement in Adult Growth Hormone Deficiency
Nyström, H. F., & Johannsson, G. (2007) · Hormone Research in Paediatrics · doi:10.1159/000097573 · Cited by 8
“We have studied whether the choice of GC was of importance for metabolic outcome in a KIMS (Pfizer International Metabolic Database) survey of GC replacement in adult ACTH-insufficient hypopituitary patients compared with ACTH-sufficient subjects before and after 1 year of GH. Patients treated with HC and prednisolone…”
ResultSelf-citationWhat factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study
Puglisi, S., Rossini, A., Tabaro, I., Cannavò, S., Ferraù, F., Ragonese, M., Borretta, G., Pellegrino, M., Dughera, F., Parisi, A., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01386-3 · Cited by 8
Guarnotta, V., Stefano, C. D., Tomasello, L., Maniscalco, L., Pizzolanti, G., Arnaldi, G., & Giordano, C. S. D. S. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae107 · Cited by 10
RetractedEmpiric Determination of the Daily Glucocorticoid Replacement Dose in Adrenal Insufficiency
Caetano, C. M., Śliwińska, A., Madhavan, P., Grady, J. J., & Malchoff, C. D. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa145 · Cited by 10
“For example, some large registry-based studies have found that patients with both primary and secondary AI on standard glucocorticoid replacement have a 2-fold greater mortality due to cardiovascular, infectious, and malignant diseases that are potentially due to over-replacement with glucocorticoids [3-5].”
BackgroundManagement of Dyslipidemia in Endocrine Diseases
Tannock, L. R. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.003 · Cited by 8
Jørgensen, N. T., Erichsen, T. M., Jørgensen, M. B., Idorn, T., Feldt‐Rasmussen, B., Holst, J. J., Feldt‐Rasmussen, U., & Klose, M. (2023) · Pituitary · doi:10.1007/s11102-022-01297-x · Cited by 9
“Replacement of hydrocortisone may result in impaired glucose metabolism in case of overtreatment [30, 31].”
BackgroundRagnarsson, Ó., Höybye, C., Jönsson, P., Feldt‐Rasmussen, U., Johannsson, G., Biller, B. M. K., & Kołtowska‐Häggström, M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0942 · Cited by 9
Self-citationChiloiro, S., Vicari, A., Mongelli, G., Costanza, F., Giampietro, A., Mattogno, P. P., Lauretti, L., Olivi, A., Marinis, L. D., Doglietto, F., et al. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09898-6 · Cited by 8
“Prednisone treatment was associated with a higher weight/height ratio, whereas cortisone acetate treatment did not appear to be associated with a worsening of glycosylated haemoglobin [153].”
BackgroundInsuficiencia suprarrenal y su tratamiento sustitutivo. Su realidad en España
Aulinas, A., Casanueva, F. F., Goñi, F., Monereo, S., Moreno, B., Pico, A. M., Puig‐Domingo, M., Salvador, J., Tinahones, F. J., & Webb, S. M. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.12.002 · Cited by 9
Chung, T., Gunganah, K., Monson, J. P., & Drake, W. M. (2015) · Clinical Endocrinology · doi:10.1111/cen.12982 · Cited by 7
Self-citationBone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency
Bioletto, F., Barale, M., Parasiliti‐Caprino, M., Giannelli, J., Campioni, L., Cappiello, V., Carlo, M. C. D., Ghigo, E., Massimo, P., & Giordano, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1234237 · Cited by 8
“This determines a mild but persistent glucocorticoid excess with a poor diurnal exposuretime profile (4, 5), which in the long-term leads to detrimental effects at different levels.”
BackgroundDonald, D. M., McDonnell, T., O’Reilly, M., & Sherlock, M. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09897-7 · Cited by 8
“Although ACTH deficiency itself is associated with increased mortality, higher doses of hydrocortisone replacement are also associated with cardiometabolic risk factors [109] and cardiovascular mortality [110, 111].”
BackgroundTouraine, P. A., Chenuc, G., & Colin, C. (2014) · Annales d Endocrinologie · doi:10.1016/j.ando.2014.09.003 · Cited by 8
“[6] Filipsson H, Monson JP, Koltowska-Haggstrom M, Mattsson A, Johannsson G.”
BackgroundHypopituitarism and Growth Hormone Deficiency
Burt, M. G., & Ho, K. K. Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00011-1 · Cited by 9
Glucocorticoid replacement therapy and fibrinolysis in patients with hypopituitarism
Peacey, S. R., Wright, D., Aye, M., & Moisey, R. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04314.x · Cited by 6
L’insuffisance surrénalienne chez l’adulte
Jublanc, C., & Bruckert, É. (2016) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2016.02.007 · Cited by 8
Llahana, S., Mulligan, K., Hirani, S. P., Wilson, S., Baldeweg, S. E., Grossman, A. B., Norton, C. S., Sharman, P., McBride, P., & Newman, S. P. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1207715 · Cited by 8
“Glucocorticoid over-replacement exposes patients to medication side effects (21, 22), cardiovascular complications (24), osteoporosis (25), depression and impaired quality of life (20, 21, 26).”
BackgroundBurger‐Stritt, S., Hahner, S., Chifu, I. O., Quinkler, M. O., Altieri, B., Hannemann, A., Völzke, H., Lang, K., Reisch, N., Pamporaki, C., et al. (2023) · Hormone and Metabolic Research · doi:10.1055/a-2190-3735 · Cited by 7
Rahvar, A., Riesel, M., Graf, T., & Harbeck, B. (2019) · Endocrine · doi:10.1007/s12020-019-01956-3 · Cited by 6
Ekstrand, E., Espósito, D., Ragnarsson, Ó., Isgaard, J., & Johannsson, G. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa160 · Cited by 6
“These data suggest that the metabolic potency of HC in relation to CA is greater than previously thought when using the conversion ratio of 4:5 for HC:CA.”
BackgroundMethodResultSelf-citationAcute interaction between hydrocortisone and insulin alters the plasma metabolome in humans
Alwashih, M. A., Stimson, R. H., Andrew, R., Walker, B. R., & Watson, D. G. (2017) · Scientific Reports · doi:10.1038/s41598-017-10200-9 · Cited by 6
Cesana‐Nigro, N., Keshvari, S., Barclay, J. L., Sorbello, J., Upham, J. W., Benham, H., Anderson, S. T., Steiger, N., Prins, J. B., & Inder, W. J. (2019) · Clinical Endocrinology · doi:10.1111/cen.14108 · Cited by 6
Addison´s disease : epidemiological and clinical studies
Björnsdóttir, S. (2014) · Figshare · Cited by 6
Adrenal crisis: incidence, clinical presentation and risk factors in patients with Addison’s disease
Scala, A., Torchio, M., Presotto, F., Mian, C., Ceccato, F., Scaroni, C. M., Betterle, C., & Sabbadin, C. (2025) · Endocrine · doi:10.1007/s12020-025-04242-7 · Cited by 6
“To analyse different GC treatment properly, we considered 20 mg hydrocortisone (HC) equivalent to 25 mg cortisone acetate (CA) [15].”
Diagnosis and Treatment of Adrenal Insufficiency
Yoo, S. J., & Jeong, H. (2012) · Hanyang Medical Reviews · doi:10.7599/hmr.2012.32.4.203 · Cited by 5
“에 비해 적지만 저용량이라도 생리적인 용량보다 다소 많은 용량을 투여하게 되면 대사에 부정적인 영향을 초래한다고 한다[37,38].”
Dullaart, R. P. F., van den Berg, G., van der Knaap, A. M., Dijck-Brouwer, J., Dallinga‐Thie, G. M., Zelissen, P. M. J., Sluiter, W. J., & van Beek, A. P. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0742 · Cited by 5
Les actualités de l’insuffisance surrénalienne
Nunes, M. L., & Tabarin, A. (2008) · Annales d Endocrinologie · doi:10.1016/s0003-4266(08)73968-4 · Cited by 5
“[31] Filipsson H, Monson JP, Koltowska-Haggstrom M, Mattsson A, Johannsson G.”
Diagnosis and Management of Adrenal Insufficiency in Children and Adults
Llahana, S., Mitchelhill, I., Yeoh, P., & Quinkler, M. O. (2019) · Springer eBooks · doi:10.1007/978-3-319-99817-6_37 · Cited by 7
Be aware of the effects of glucocorticoids on SIADH: A case report
Li, H., Huang, L., Wu, G., Chen, X., Zheng, Q., Su, F., Liang, M., & Chen, X. (2019) · Medicine · doi:10.1097/md.0000000000014295 · Cited by 5
“Patients accepted >20mg/d hydrocortisone treatment are exposed in a higher risk of adverse metabolism.([10]) This patient was admitted to hospital by refractory hyponatremia after craniocerebral trauma, and was administered long-term glucocorticoid replacement therapy.”
BackgroundRaut, M. S., Kar, S., Maheshwari, A., Shivnani, G., & Dubey, S. (2019) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytz145 · Cited by 7
Endocrinological diagnosis and replacement therapy for hypopituitarism
Espósito, D., Johannsson, G., & Ragnarsson, Ó. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819949-7.00027-5 · Cited by 7
Self-citationRensing, K. L., van Duyvenvoorde, H. A., Cramer, M. J., Teske, A. J., Prokop, M., Stroes, E. S. G., Wit, J. M., Hermus, A. R. M. M., & Twickler, T. B. (2011) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2011.05.004 · Cited by 5
Uncertainties in endocrine substitution therapy for central hypocortisolism
Swords, F. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59602-4.00026-5 · Cited by 5
Muscogiuri, G., Albertelli, M., Arnaldi, G., Barrea, L., Bellastella, G., Bonomi, M., Caputo, M., Caprio, M., Cignarelli, A., Gioia, L. D., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02862-y · Cited by 4
“Regardless of the formulation used, GC overtreatment should be avoided, with recommended target daily doses of 15–25 mg/day for hydrocortisone or 3–5 mg/day for prednisolone [ 233, 234].”
Salivary Cortisol Measurement Contamination After Oral Hydrocortisone: A Randomized Crossover Trial
Chihaoui, M., Mouelhi, Y., Hammami, B., Oueslati, I., Khessairi, N., Chaker, F., Yazidi, M., & Feki, M. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2271-0700 · Cited by 4
“GC substituted patients are often overtreated and may develop an adverse metabolic profile with increased waist circumference, glycated hemoglobin, and plasma lipids [1, 2].”
BackgroundAbdallah, N., Mohamoud, A. A., Kearns, A., Abdallah, M., & Linzer, M. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102641 · Cited by 4
Stergianos, S., Spelman, T. D., Eriksson, D., Öster, S., Björnsdóttir, S., Kämpe, O., Skov, J., & Bensing, S. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20085 · Cited by 5
“Treatment of adrenal insufficiency with synthetic gluco-corticoids has also been associated with adverse metabolic effects [53].”
Reznik, Y. (2016) · La Presse Médicale · doi:10.1016/j.lpm.2016.05.007 · Cited by 4
Prediction of diabetes mellitus induced by steroid overtreatment in adrenal insufficiency
Guarnotta, V., Tomasello, L., & Giordano, C. S. D. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-04904-w · Cited by 4
Ressing, M., Becker, C., Müller, C. E., Mahmoudpour, S. H., Calaminus, G., Langer, T., Erdmann, F., Voigt, M., Kaiser, M., Kaatsch, P., et al. (2023) · Cancer Reports · doi:10.1002/cnr2.1811 · Cited by 4
Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma
Altieri, B., Kimpel, O., Megerle, F., Detomas, M., Chifu, I. O., Fuß, C. T., Quinkler, M. O., Kroiß, M., & Faßnacht, M. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae007 · Cited by 4
Wasmuth, A., van de Loo, I., Domberg, J., & Harbeck, B. (2025) · Endocrine · doi:10.1007/s12020-025-04192-0 · Cited by 4
“Nevertheless, we could demonstrate that still a considerable proportion of AI patients had more than one glucocorticoid replacement medication including dexamethasone that increases CVR even more ([6, 32]).”
Müller, M., Beiglböck, H., Fellinger, P., Winhofer, Y., Luger, A., Gschwandtner, M. E., Willfort‐Ehringer, A., Koppensteiner, R., Kautzky‐Willer, A., Krebs, M., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01309-2 · Cited by 4
Cardiovascular outcome in patients with adrenal insufficiency—a therapeutic dilemma
Rahvar, A., Riesel, M., Graf, T., & Harbeck, B. (2021) · Endocrine · doi:10.1007/s12020-020-02571-3 · Cited by 4
Harbeck, B., Kropp, P. A., & Kreitschmann‐Andermahr, I. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1153595 · Cited by 5
“GC replacement therapy itself (in particular HC doses > 20 mg/d) adversely affects some of the well-known risk factors for cardiovascular disease (CVD), for example, obesity, hypertension, diabetes, and hyperlipoproteinemia (8, 13, 14).”
BackgroundJørgensen, N. T., Boesen, V. B., Borresen, S. W., Christoffersen, T., Jørgensen, N. R., Plomgaard, P., Christoffersen, C., Watt, T., Feldt‐Rasmussen, U., & Klose, M. (2024) · Endocrine · doi:10.1007/s12020-024-03711-9 · Cited by 4
“Both supraphysiological replacement doses and the unphysiological timing of the replacement treatment seem to increase morbidity and mortality in patients with adrenal insuf fi ciency [7, 31, 32].”
BackgroundLi, L., Yang, G., Liao, G., Mei, J., Li, L., Wang, C., Yuan, Y., Shi, Y., Liu, J., Zhong, Z., et al. (2017) · Steroids · doi:10.1016/j.steroids.2017.09.005 · Cited by 4
Hypopituitarism—needs modern individualized treatment
Olsson, D. S., & Bengtsson, B. (2016) · Endocrine · doi:10.1007/s12020-016-1211-3 · Cited by 4
“adverse metabolic profile in hypopituitary patients [6, 17].”
Adrenal Insufficiency Associated Cardiomyopathy, From Molecule to Clinic: A Comprehensive Review
Bazgir, N., Soltani, A., Mohajer, Z., Tabari, M. A. K., & Eslami, V. (2025) · Health Science Reports · doi:10.1002/hsr2.70702 · Cited by 3
Hamidi, O., Auchus, R. J., Correa, R. R., Levine, A. C., Wierman, M. E., Hartzell, A. L., Lin, V. H., & Bancos, I. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag147 · Cited by 4
GREGORIO, C. D., Andò, G., Cannavò, S., Cotta, O. R., Trio, O., Cusmà-Piccione, M., Trimarchi, F., & Curtò, L. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.10.017 · Cited by 3
“[32] had demonstrated that the hydrocortisone equivalent dose of at least 20 mg/daily was associated with an unfavorable metabolic profile in adult hypopituitary patients.”
BackgroundEmming, C., Geks, A. K., Sajadihezaveh, S., Rieker, T., Brutsche, J., Volk, H. A., & Rieder, J. C. (2025) · Frontiers in Veterinary Science · doi:10.3389/fvets.2025.1544750 · Cited by 3
“A recent study in humans found that long-acting synthetic steroids (e.g., prednisolone, dexamethasone), used in people with hypopituitarism, are linked to a higher risk of adverse metabolic effects such as weight gain, dyslipidemia, and diabetes mellitus (39).”
Han, M.-M., Zhang, J., Liu, Z., Xu, L., Bai, T., Xiang, C.-Y., Zhang, J., Lv, D.-Q., Liu, Y.-F., Wei, Y., et al. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i7.1112 · Cited by 3
Cardiovascular Risk Factors in Sheehan’s Syndrome: A Case-Control Study
Agrawal, M. B., Yadav, S. C., Singh, S. K., Kumar, S., Chatterjee, K., & Garg, N. K. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_297_23 · Cited by 3
Slagboom, T. N. A., van Bunderen, C. C., van der Lely, A. J., & Drent, M. L. (2024) · Pituitary · doi:10.1007/s11102-024-01448-2 · Cited by 2
“This is in line with previous results from the KIMS database, which found three new cases of myocardial infarction and eight new cases of stroke in the glucocorticoid treated group, compared with no events in the non-glucocorticoid group [15].”
BackgroundResultChifu, I. O., Richter, A.-L., Lippert, J., Detomas, M., Scheuermann, C., Herterich, S., Harbeck, B., Freytag, J., Altieri, B., & Hahner, S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf383 · Cited by 2
Ten-year trends in adrenal insufficiency admissions
Shaka, H., Manz, S., El‐amir, Z., Wani, F., Salim, M., & Kichloo, A. (2022) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2022.2039503 · Cited by 2
“Conditions such as metabolic syndrome, diabetes, and obesity affect the titration of glucocorticoid medications.(16) Incorrect dosing of glucocorticoid replacement increases the risk of hospitalization in patients with AI.”
BackgroundHydrocortisone Replacement in Disorders of Sex Development
Blankenstein, O. (2014) · Endocrine development · doi:10.1159/000363752 · Cited by 2
Adrenal insufficiency and adrenal replacement therapy. Current status in Spain
Aulinas, A., Casanueva, F. F., Goñi, F., Monereo, S., Moreno, B., Pico, A. M., Puig‐Domingo, M., Salvador, J., Tinahones, F. J., & Webb, S. M. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.12.004 · Cited by 4
Broussard, J., & Mitre, N. (2015) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0473 · Cited by 2
“Furthermore, long-term high-dose hydrocortisone replacement can affect bone metabolism and increase cardiovascular and metabolic risk factors (10).”
Kolnes, A. J., Øystese, K. A., Dahlberg, D., Berg–Johnsen, J., Niehusmann, P., Pahnke, J., Bollerslev, J., & Jørgensen, A. P. (2020) · Acta Neurochirurgica · doi:10.1007/s00701-019-04068-z · Cited by 3
Aspects of diagnosis and treatment of hypopituitarism in adult life
Nyström, H. F. (2009) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 2
Improved salivary cortisol rhythm with dual-release hydrocortisone
Ceccato, F., Selmin, E., Sabbadin, C., Costa, M. D., Antonelli, G., Plebani, M., Barbot, M., Betterle, C., Boscaro, M., & Scaroni, C. M. (2018) · Endocrine Abstracts · doi:10.1530/endoabs.56.p56 · Cited by 2
Mutlu, Ü., Rasulova, N., Hacışahinoğulları, H., Yalın, G. Y., Gül, N., Üzüm, A. K., & Selçukbiricik, Ö. S. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02668-4 · Cited by 1
“In addition, the risk of cardiovascular disease and the prevalence of comorbidities such as abdominal obesity, hypertension, dyslipidemia, diabetes, and osteoporosis are also increased in this population [ 26 – 28 ].”
Iglesias, P. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2649164 · Cited by 1
Šimůnková, K., & Husebye, E. S. (2016) · Frontiers of hormone research · doi:10.1159/000443920 · Cited by 1
Glucocorticoid Replacement in Man
Russell, G. M., Løvås, K., & Lightman, S. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803592-4.00078-x · Cited by 1
Betterle, C., & Zanchetta, R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-384929-8.00042-3 · Cited by 1
Espiard, S., McQueen, J., Sherlock, M., Ragnarsson, Ó., Bergthorsdottir, R., Burman, P., Dahlqvist, P. M., Ekman, B., Engstrom, B. E., Skrtic, S., et al. (2021) · Yearbook of pediatric endocrinology · doi:10.1530/ey.18.8.5 · Cited by 1
Self-citationInterface de doenças endocrinológicas com repercussões psiquiátricas: uma revisão de literatura
Lafayette, D. D. S. A., Urquiza, P. A. C., Brito, E. M. C., Costa, S. P. G. A., & Cantilino, A. (2021) · Debates em Psiquiatria · doi:10.25118/2763-9037.2021.v11.271 · Cited by 1
“Em pacientes com doença de Addison, o córtex adrenal é incapaz de aumentar a secreção de hormônio à estimulação [26, 27].”
Hipopituitarismo. Panhipopituitarismo
Fernández-Rodríguez, E., Bernabeu, I., & F., C. F. (2012) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(12)70381-5 · Cited by 1
Ahmed, M. I., & Maliyakkal, A. M. (2022) · Cureus · doi:10.7759/cureus.25061 · Cited by 1
“Although HC has been reported to increase CVR at a dose >20 mg/day, our patient was receiving a dose of 20 mg/day [9].”
BackgroundAbdallah, N., Mohamoud, A. A., Daher, H., Abdallah, M., & Mehfooz, A. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.103835 · Cited by 1
Simha, V. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_15 · Cited by 3
Glucocorticoids - outcome in patients with glucocorticoid deficiency and Cushing's syndrome
Ragnarsson, Ó. (2012) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Vargas‐Uricoechea, H., & Ruiz, D. E. M. (2014) · Actualidad Contable FACES · Cited by 1
Dullaart, R. P. F. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02142.x · Cited by 1
Steroid Replacement in Adrenal Insufficiency
Blair, J., Debono, M., & Ross, R. J. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64307-6 · Cited by 1
Long-Term Complications of Hypercortisolism
Pivonello, R., Iacuaniello, D., Simeoli, C., Martino, M. C. D., & Colao, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64305-2 · Cited by 2
5: Diabetes Secondary to Endocrinopathies
Silverstein, J. M., Sterl, K., Cartier, J. L., Cruz‐Bravo, P., Davis, C., Sadiq, S., & McGill, J. B. (2018) · American Diabetes Association eBooks · doi:10.2337/9781580406666.05 · Cited by 1
Antropometry in HIV Patients: Effects of Recombinant Human Growth Hormone
Luzi, L., Terruzzi, I., & Benedini, S. (2012) · Springer eBooks · doi:10.1007/978-1-4419-1788-1_154
Lee, P. P., & Ho, K. K. Y. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-177-6_3 · Cited by 1
Overvloed en onbehagen. Uitdagingen voor de moderne endocrinologie.
Smit, J. W. A. (2008) · Leiden Repository (Leiden University)
Hypothalamic/Pituitary Morbidity in Skull Base Pathology
Lee, P., Ho, K. K. Y., & Greenfield, J. R. (2011) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2011.06.010 · Cited by 1
Model diseases for studies of autoimmunity.
Dalin, F. (2015) · DiVA (Digitala Vetenskapliga Arkivet)
Long-term steroid hormone concentrations in healthy children, in obesity, and in disease
Noppe, G. (2016) · EUR Research Repository (Erasmus University Rotterdam)
Giordano, R. (2018) · Clinical Endocrinology · doi:10.1111/cen.13748
Salah, D. B., Charfi, N., Elleuch, M., Kacem, F. H., Rekik, N., Mnif, M., Mnif, F., & Abid, M. (2018) · Pan African Medical Journal · doi:10.11604/pamj.2018.30.251.12546 · Cited by 1
“Le rôle métabolique délétère d'un surdosage en glucocorticoïdes est également illustré par les résultats issus de la cohorte de patients hypopituitaires substitués par hormone de croissance de l'étude KIMS [10].”
BackgroundInfluentialTritos, N. A., & Klibanski, A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-416706-3.00005-2
Biscotto, I. P. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2020.tde-11062021-134324
تاثير الکالسيوم وفيتامين د وبذور الشيا على الفئران المصابه بهشاشة العظام
خليل, ه. ف. م. خ., العزيز, ا. ع., & El-Rahman, A. A. (2021) · Mağallaẗ Al-Iqtiṣād Al-Manzilī - Ǧāmiʿaẗ Al-Munūfiyyaẗ · doi:10.21608/mkas.2021.96073.1079
Lubitz, S. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-76097-3.00020-x
Betterle, C., Presotto, F., & Zanchetta, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00042-7
(2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f4f084
Hypopituitarism and Growth Hormone Deficiency
Lee, P., & Ho, K. K. Y. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00013-7 · Cited by 2
Metadata
- Authors
- Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G.
- Affiliations
- Department of Endocrinology (H.F., G.J.), Sahlgrenska Academy at Gothenburg’s University, SE-413 45 Gothenburg, Sweden
- St Bartholomew's Hospital (GB)
- KIGS/KIMS/ACROSTUDY Medical Outcomes (M.K.-H., A.M.), Endocrine Care, Pfizer, SE-191 90 Sollentuna, Sweden
- Pfizer (Sweden) (SE)
- University of Gothenburg (SE)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-10-01
- Volume
- 91
- Issue
- 10
- Pages
- 3954-3961
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2137769079
- Cited by
- 321
- References
- 48
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 25 · 2023: 12 · 2022: 13 · 2021: 17 · 2020: 24 · 2019: 18 · 2018: 16 · 2017: 16 · 2016: 25 · 2015: 20 · 2014: 23 · 2013: 12 · 2012: 19
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Chalmers Research (Chalmers University of Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- hypopituitarism, glucocorticoid replacement therapy, cortisol, cortisone acetate, prednisolone, dexamethasone, growth hormone replacement therapy, metabolic profile, body mass index, waist circumference, serum lipids, HbA1c, insulin-like growth factor I, diabetes mellitus, stroke, myocardial infarction, comorbidities, glucocorticoid dose
- MeSH terms
- Adrenocorticotropic Hormone, Adult, Aged, Female, Glucocorticoids, Humans, Hypopituitarism, Insulin-Like Growth Factor I, Lipids, Male, Middle Aged, Risk Factors, Growth Hormone, Comorbidity, Body Mass Index, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.